DIGESTIVE DUAL PHASE ENZYMES 5400 UNIT
CELLULASE (ASPERGILLUS ORYZAE) : 5400 UNIT LACTASE (ASPERGILLUS ORYZAE) : 3000 UNIT LIPASE (RHIZOPUS NIVEUS) : 2250 UNIT AMYLASE (ASPERGILLUS ORYZAE) : 3400 UNIT PROTEASE (ASPERGILLUS ORYZAE) : 11000 UNIT · DIN 02241060 · ABUNDANCE NATURALLY LTD
Health Canada status: CANCELLED PRE MARKET
What is DIGESTIVE DUAL PHASE ENZYMES?
DIGESTIVE DUAL PHASE ENZYMES 5400 UNIT contains CELLULASE (ASPERGILLUS ORYZAE) : 5400 UNIT LACTASE (ASPERGILLUS ORYZAE) : 3000 UNIT LIPASE (RHIZOPUS NIVEUS) : 2250 UNIT AMYLASE (ASPERGILLUS ORYZAE) : 3400 UNIT PROTEASE (ASPERGILLUS ORYZAE) : 11000 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02241060, held by ABUNDANCE NATURALLY LTD, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 20-Jun-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02241060 |
|---|---|
| Brand name | DIGESTIVE DUAL PHASE ENZYMES |
| Generic / active ingredient | CELLULASE (ASPERGILLUS ORYZAE) : 5400 UNIT LACTASE (ASPERGILLUS ORYZAE) : 3000 UNIT LIPASE (RHIZOPUS NIVEUS) : 2250 UNIT AMYLASE (ASPERGILLUS ORYZAE) : 3400 UNIT PROTEASE (ASPERGILLUS ORYZAE) : 11000 UNIT |
| Manufacturer | ABUNDANCE NATURALLY LTD |
| Strength | 5400 UNIT |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC) |
| AHFS class | 44:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 20-Jun-2017 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02241060 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2241060 |
| Brand name | DIGESTIVE DUAL PHASE ENZYMES |
| Active ingredient / INN | CELLULASE (ASPERGILLUS ORYZAE) : 5400 UNIT LACTASE (ASPERGILLUS ORYZAE) : 3000 UNIT LIPASE (RHIZOPUS NIVEUS) : 2250 UNIT AMYLASE (ASPERGILLUS ORYZAE) : 3400 UNIT PROTEASE (ASPERGILLUS ORYZAE) : 11000 UNIT |
| ATC code | A09AA02 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A09 |
| AHFS class | 44:00.00 |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| Biosimilar biologic | No |
| Market authorization holder | ABUNDANCE NATURALLY LTD |
Which pack is which?
| Strength on the label | 5400 UNIT |
|---|---|
| Dosage form | CAPSULE |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code A09AA02 MULTIENZYMES (LIPASE, PROTEASE ETC). 14 of 65 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| COTAZYM | 35000 UNIT | CAPSULE (IMMEDIATE RELEASE) | ORGANON CANADA INC. | MARKETED | DIN 00263818 |
| COTAZYM ECS 20 | 25000 UNIT | CAPSULE (DELAYED RELEASE) | ORGANON CANADA INC. | MARKETED | DIN 00821373 |
| COTAZYM ECS 8 | 10800 UNIT | CAPSULE (DELAYED RELEASE) | ORGANON CANADA INC. | MARKETED | DIN 00502790 |
| CREON MINIMICROSPHERES 10 | 10000 UNIT | CAPSULE (DELAYED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02200104 |
| CREON MINIMICROSPHERES 25 | 25000 UNIT | CAPSULE (DELAYED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 01985205 |
| CREON MINIMICROSPHERES 35 | 35700 UNIT | CAPSULE (DELAYED RELEASE) | BGP PHARMA ULC | MARKETED | DIN 02494639 |
| CREON MINIMICROSPHERES MICRO | 5000 UNIT / 100 MG | GRANULES FOR SUSPENSION, DELAYED RELEASE | BGP PHARMA ULC | MARKETED | DIN 02445158 |
| PANCREASE MT 10 | 43750 UNIT | CAPSULE (DELAYED RELEASE) | VIVUS LLC. | MARKETED | DIN 00789437 |
| PANCREASE MT 16 | 70000 UNIT | CAPSULE (DELAYED RELEASE) | VIVUS LLC. | MARKETED | DIN 00789429 |
| PANCREASE MT 2 | 6200 UNIT | CAPSULE (DELAYED RELEASE) | VIVUS LLC. | MARKETED | DIN 02503433 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.